These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9654837)

  • 1. Proglumide as a morphine adjunct in cancer pain management.
    Bernstein ZP; Yucht S; Battista E; Lema M; Spaulding MB
    J Pain Symptom Manage; 1998 May; 15(5):314-20. PubMed ID: 9654837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain.
    McCleane GJ
    Anesth Analg; 1998 Nov; 87(5):1117-20. PubMed ID: 9806692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proglumide potentiates morphine analgesia for acute postsurgical pain.
    Lavigne GJ; Hargreaves KM; Schmidt EA; Dionne RA
    Clin Pharmacol Ther; 1989 Jun; 45(6):666-73. PubMed ID: 2659236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cholecystokinin antagonist proglumide enhances the analgesic effect of dihydrocodeine.
    McCleane GJ
    Clin J Pain; 2003; 19(3):200-1. PubMed ID: 12792559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment.
    Roca G; Aguilar JL; Gomar C; Mazo V; Costa J; Vidal F
    Pain; 1996 Dec; 68(2-3):239-43. PubMed ID: 9121810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist.
    Price DD; von der Gruen A; Miller J; Rafii A; Price C
    Anesth Analg; 1985 Aug; 64(8):801-6. PubMed ID: 4014744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain.
    McCleane GJ
    Neurosci Lett; 2003 Feb; 338(2):151-4. PubMed ID: 12566175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide.
    Watkins LR; Kinscheck IB; Mayer DJ
    Brain Res; 1985 Feb; 327(1-2):169-80. PubMed ID: 3838690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of proglumide, a cholecystokinin antagonist, to potentiate clinical morphine analgesia. A randomized double-blind postoperative study using patient-controlled analgesia (PCA).
    Lehmann KA; Schlüsener M; Arabatsis P
    Anesth Analg; 1989 Jan; 68(1):51-6. PubMed ID: 2642668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.
    Collins JJ; Geake J; Grier HE; Houck CS; Thaler HT; Weinstein HJ; Twum-Danso NY; Berde CB
    J Pediatr; 1996 Nov; 129(5):722-8. PubMed ID: 8917240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial.
    Israel FJ; Parker G; Charles M; Reymond L
    J Pain Symptom Manage; 2010 Mar; 39(3):548-54. PubMed ID: 20083373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study.
    Mercadante S; Serretta R; Casuccio A
    J Pain Symptom Manage; 2001 May; 21(5):369-72. PubMed ID: 11369156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain.
    Watanabe S; Pereira J; Tarumi Y; Hanson J; Bruera E
    J Palliat Med; 2008 May; 11(4):570-4. PubMed ID: 18454609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antinociceptive effect of intracerebroventricular administration of cholecystokinin antagonist in nerve-ligated mice.
    Zarrindast MR; Samiee F; Rezayat M
    Pharmacol Toxicol; 2000 Oct; 87(4):169-73. PubMed ID: 11097270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment.
    Kellstein DE; Mayer DJ
    Brain Res; 1990 May; 516(2):263-70. PubMed ID: 2364292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone for cancer pain.
    Nicholson AB
    Cochrane Database Syst Rev; 2004; (2):CD003971. PubMed ID: 15106230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat.
    Friedrich AE; Gebhart GF
    J Pharmacol Exp Ther; 2000 Feb; 292(2):538-44. PubMed ID: 10640290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzodiazepine mediated antagonism of opioid analgesia.
    Gear RW; Miaskowski C; Heller PH; Paul SM; Gordon NC; Levine JD
    Pain; 1997 May; 71(1):25-9. PubMed ID: 9200170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proglumide, a cholecystokinin receptor antagonist, reduces neuroleptic action in Huntington's chorea.
    Piolti R; Appollonio I; Perego M; Pozzi C; Rovati L; Ferrarese C; Frattola L
    Eur Neurol; 1995; 35(6):344-8. PubMed ID: 8591802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.